It was learned from Tianjin University on the 21st that the first in vitro artificial heart independently developed and designed by China was recently made in Tianjin. In the process of making the heart, materials successfully prepared by scientific researchers were used to solve key problems such as blood compatibility and bionic modification of the inner surface. It indicates that China has mastered the core technology of in vitro artificial heart making, and has become a country that has mastered the independent intellectual property rights of this core technology after Germany, the United States, and Canada. The more sophisticated "Tianjin Heart" can not only gradually realize the clinical replacement of similar foreign products, but also smaller in size (only 200 grams in weight, lighter than the adult heart), the price is expected to be only 1/4 to 1 of similar foreign products / 7. Many patients with advanced heart disease are expected to greatly reduce the medical burden and rekindle hopes.
Next year will be used in clinical trials of animals
Good news came from Tianjin University recently. The domestic cardiac extracorporeal assist device jointly developed by Tianjin University-GKSS Research Center Biomaterials and Regenerative Medicine Joint Laboratory, Tianjin Chest Hospital and Chinese Academy of Sciences has been basically processed. According to Professor Feng Yakai, Department of Polymers, School of Chemical Engineering, Tianjin University, who is in charge of the project, the core problems solved by this joint research in China are the material preparation and blood compatibility of the extracorporeal heart assist device, and the processing of the "artificial heart" And technical problems such as bionic modification of the inner surface after molding.
After more than a year of hard work by technicians, the domestic heart extracorporeal device made of new material polyurethane has been basically processed and molded, weighing about 200 grams, slightly lighter than the heart of adults, allowing patients to move relatively freely and at home recovery treatment. Next year, "Tianjin Heart" will conduct animal trials, and then conduct clinical trials the following year, and continuously optimize the processing technology during the trial. "We will make repeated trials to ensure maximum recovery for patients and come up with the safest 'Tianjin Heart' for the benefit of patients before they can be officially put into production." Feng Yakai said.
Cost reduced to 30,000 to 50,000 scale production in Binhai New Area
It is understood that this project is a major project of Tianjin Science and Technology Support Program. Its implementation can improve the level of biomaterials and manufacturing technology in China, promote the clinical application of localized artificial hearts, and make major breakthroughs in heart transplantation and artificial heart treatment technology, reducing the final The mortality rate of end-stage heart disease improves the quality of life of patients and enables the treatment of end-stage heart disease in this city to reach the international advanced level. It is expected that the implementation of this project will reduce the cost of extracorporeal heart assist devices to 30,000 to 50,000 yuan, and bring more healing gospel to more patients.
It is reported that the Department of Polymers of the School of Chemical Engineering of Tianjin University and the German GKSS Research Center in the fields of biomaterials and regenerative medicine will complete large-scale production with the help of Binhai New Area enterprises to promote the industrialization of regenerative medical materials and related products in China.
"Berlin Heart" wins time for rescue
According to reports, heart transplantation is currently the only effective way to cure advanced heart disease, especially heart failure, but in view of the "brain death" in China is still in the legislative blank stage, and the number of organ donations and clinical needs are seriously out of balance, many lives can only wait Withered slowly.
It is reported that before finding a matching heart donor, the patient can only rely on "artificial heart" as a substitute to circulate metabolism to maintain life until the patient recovers or successfully undergoes heart transplant surgery. The extracorporeal heart assist device is a kind of "artificial heart". It was invented in Berlin, Germany in 1992. It is also known as the "Berlin Heart". It is mainly used for end-stage heart disease and transition before heart transplantation where medicine and surgical treatment are ineffective. Support, the data shows that the "Berlin Heart" has been widely used in Europe and the United States, successfully saving the lives of thousands of people.
In the past, the use of "Berlin Heart" in China's clinical practice could only be purchased from abroad, and the price was as high as more than 200,000 yuan. However, the domestic imitation "Berlin Heart" has not been used in clinic because of immature materials and rough technology, which has made the treatment of advanced heart disease in China Be in a backward state. The localization of cardiac extracorporeal devices has become the focus of research.
Indelible Ink,Electoral Commission Ink,Silver Nitrate Ink,Purple Voting Ink
Huhua Stationary Co., Ltd , https://www.huhuastamp.com